Aarti Drugs has finalized a significant leadership transition to strengthen its governance framework, with changes effective October 1, 2026. The Board of Directors approved the elevation of Rashesh C. Gogri to Chairman in addition to his existing role as Managing Director, and the appointment of Adhish P. Patil as Managing Director. Concurrently, Prakash M. Patil will retire from his executive roles as Chairman, Managing Director, and Chief Executive Officer after nearly a decade of leadership since 2014.

Leadership Transition Details

The restructuring aims to balance continuity with renewal by promoting internal leaders who possess deep institutional knowledge. The following table outlines the key appointments and departures:

Rashesh C. Gogri, who has served as Managing Director since September 2014 and previously as Whole-time Director from October 2012, brings over 27 years of experience in production, marketing, and project implementation. He also serves as Vice-Chairman & Managing Director of Aarti Industries Limited and Chairman of Aarti Pharmalabs Limited.

Adhish P. Patil, currently the Chief Financial Officer since April 2014, will assume the role of Managing Director. He holds an MBA in Finance and Marketing from the University of Florida's Warrington College of Business Administration, where he graduated as a gold medallist. His appointment is subject to shareholder approval at the ensuing Annual General Meeting.

Strategic Implications

Prakash M. Patil, who has been associated with Aarti Drugs since its inception in 1984, will step back from executive responsibilities but will continue to provide guidance and strategic support to ensure a smooth transition. This move reflects a structured approach to succession planning, preserving technical expertise while positioning the company for faster execution across manufacturing, R&D, and commercial functions.

What the Numbers Show

The retention of senior leadership within the organization signals stability for investors. By elevating executives who have grown within the company, Aarti Drugs mitigates the risks often associated with external hires. The transition maintains the company's long-term strategic direction, focusing on scaling operations in Active Pharmaceutical Ingredients (APIs) and specialty chemicals through its 14 manufacturing facilities across Maharashtra, Gujarat, and Himachal Pradesh.

Aarti Drugs Limited has scheduled its Quarterly Earnings Conference Call for investors and analysts on Monday, August 3, 2026, at 11:00 AM IST. The call has been convened to discuss the company's financial performance for the quarter ended June 30, 2026 (Q1 FY27). The intimation was filed under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and signed by Company Secretary & Compliance Officer Rushikesh Vivek Deole.

Conference Call Details

The earnings call will be accessible to participants across multiple geographies. The scheduled timings across key time zones are as follows:

Key Participants

The following senior representatives of Aarti Drugs are scheduled to participate in the conference call:

• Mr. Harshit Savla — Joint Managing Director
• Mr. Harit Shah — Whole Time Director
• Mr. Adhish Patil — Chief Finance Officer & Chief Operating Officer
• Mr. Vishwa Savla — Managing Director, Pinnacle Life Science Private Limited

Dial-In Information

Investors and analysts wishing to join the call may use the following country-specific dial-in numbers:

For RSVP and further assistance, participants may contact Strategic Growth Advisors Pvt. Ltd. — Mr. Deven Dhruva at +91 98333 73300 or Ms. Krisha Shrimankar at +91 87797 99281.